FDA Approves L-Glutamine Powder for the Treatment of Sickle Cell Disease

U.S. Food and Drug Administration


On July 7, 2017, the U.S. Food and Drug Administration (FDA) approved L-glutamine oral powder (Endari, Emmaus Medical, Inc.) for oral administration to reduce the acute complications of sickle cell disease in adult and pediatric patients five years and older.

View Article @ voice.ons.org

ONS Articles

Dive into a rich source of oncology nursing expertise with ONS articles.

View All Articles